Indian Journal of Endocrinology and Metabolism

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 23  |  Issue : 3  |  Page : 278--281

Prospective study of bethesda categories III and IV thyroid nodules: Outcomes and predictive value of BRAFV600E mutation


Shiga Rappai Chirayath, Praveen V Pavithran, Nithya Abraham, Vasantha Nair, Nisha Bhavani, Harish Kumar, Usha V Menon, Arun S Menon 
 Department of Endocrinology, Amrita Institute of Medical Sciences and Research Center, Kochi, Kerala, India

Correspondence Address:
Praveen V Pavithran
Department of Endocrinology, Amrita Institute of Medical Sciences and Research Center, Ponekkara - 682 041, Kochi, Kerala
India

Introduction: Atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has emerged as the most controversial category because of its heterogeneity and inconsistent reporting. There is a definite paucity in data available from the Indian subcontinent about the outcome of nodules carrying Bethesda category III or Bethesda category IV diagnoses. Aims and Objectives: The primary objective of our study was to determine the malignancy rate in Bethesda categories III and IV nodules. The secondary objectives were to determine predictive value of BRAFV600E mutation analysis on indeterminate thyroid nodules, predictive value of Thyroid image reporting and data system (TI-RADS) in malignancy prediction and to study the common histological variants in indeterminate nodules. Materials and Methods: This prospective study included 176 consecutive nodules of Bethesda categories III and IV, diagnosed over a period of 2 years from August 2015 to August 2017. A part of the fine needle aspirate was used to perform the BRAFV600E mutation analysis. The malignancy risk associated with these Fine needle aspiration Cytology categories were discussed with the patients. Those with Bethesda category IV diagnosis was advised surgery, whereas those with Bethesda category III were given the options of close follow-up with repeat FNA in 3 months or immediate surgery. Results: In our prospective study, there were 176 consecutive samples of categories III (140/79.5%) and IV (36/20.5%). Seventy-five (53.6%) category III nodules and 29 (80.6%) category IV nodules underwent immediate surgical excision. Fifty-five consecutive indeterminate cytology nodules were subjected for BRAFV600E. One of the samples was found to be positive for BRAF T1799A (V600E) mutation. The second sample harboured a missense mutation at position 1819 (TCC--GCC), wherein the codon 607 (TCC) coding for serine was substituted by alanine (GCC) which is a variant of unknown significance. In our study, the malignancy rate of Bethesda categories III and IV, which were triaged for immediate surgery were 54.6% and 72.4%, respectively. Conclusion: Malignancy rate in Category III at our center was much higher than that described by ATA and by other studies published from centers around the world, including the only two studies from India. In view of the strikingly high malignancy rate in these indeterminate nodules, strong consideration to surgery should be given to patients with FNA results suggesting these two categories. BRAFV600E mutation analysis in FNA specimen has limited utility in improving the preoperative diagnostic rate for malignancy.


How to cite this article:
Chirayath SR, Pavithran PV, Abraham N, Nair V, Bhavani N, Kumar H, Menon UV, Menon AS. Prospective study of bethesda categories III and IV thyroid nodules: Outcomes and predictive value of BRAFV600E mutation.Indian J Endocr Metab 2019;23:278-281


How to cite this URL:
Chirayath SR, Pavithran PV, Abraham N, Nair V, Bhavani N, Kumar H, Menon UV, Menon AS. Prospective study of bethesda categories III and IV thyroid nodules: Outcomes and predictive value of BRAFV600E mutation. Indian J Endocr Metab [serial online] 2019 [cited 2019 Oct 21 ];23:278-281
Available from: http://www.ijem.in/article.asp?issn=2230-8210;year=2019;volume=23;issue=3;spage=278;epage=281;aulast=Chirayath;type=0